|
May 27
|
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
|
|
May 22
|
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 13
|
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
|